Why Biodesix Inc (BDSX) Stock Fell 8.5% on Nov 10, 2026
as of Tuesday, 9:57 AM ET
The reason we found
Analyst trims Biodesix target despite maintaining Buy rating
HC Wainwright lowered its price target from $38 to $34, signaling reduced near-term valuation expectations even while keeping a Buy rating. That downgrade can pressure shares, whereas the planned AMP presentation is generally positive but less likely to drive a sharp decline.
analyst price target cutmedium confidence
Sources 4
- Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meetingmarkets.businessinsider.com
- Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meetingfinance.yahoo.com
- Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meetingfinnhub.io
- HC Wainwright & Co. Maintains Buy on Biodesix, Lowers Price Target to $34finnhub.io
Our call
Buy moredated Nov 10, 2026
Biodesix fell 53% over the past four trading days after its Nov 5 report missed profit forecasts by 1.4%, but its sales grew 31% over the past year. We'd stop buying if Biodesix's next report shows sales growth below 16% or misses profit forecasts.
Other moves on Nov 10
- HIMS−16.5%Earnings miss and weaker outlook trigger Hims & Hers selloff
- LFVN−13.6%LifeVantage Stock Falls After Revenue Drops 22%
- QLYS−13.3%Qualys Falls Despite Earnings Beat on Tepid Revenue Outlook
- ACAD+10.7%Revenue Beat and Guidance Lift Acadia Shares
- ASTS−8.7%AST SpaceMobile slides after earnings miss and price-target cut
- SERV−8.4%Analyst lowers Serve Robotics price target, pressuring shares